{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:09:38Z","timestamp":1784761778953,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"natural science foundation of guangdong province","doi-asserted-by":"publisher","award":["No. 2020A1515110193"],"award-info":[{"award-number":["No. 2020A1515110193"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Blau syndrome (BS), a rare, autosomal-dominant autoinflammatory syndrome, is characterized by a clinical triad of granulomatous recurrent uveitis, dermatitis, and symmetric arthritis and associated with mutations of the nucleotide-binding oligomerization domain containing 2 (NOD2) gene. Aim of this study was to assess the efficacy of tofacitinib in Chinese paediatric patients with BS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Tofacitinib was regularly administered to three BS patients (Patient 1, Patient 2, and Patient 3) at different dosages: 1.7\u2009mg\/day (0.11\u2009mg\/kg), 2.5\u2009mg\/day (0.12\u2009mg\/kg), and 2.5\u2009mg\/day (0.33\u2009mg\/kg). The clinical manifestations of the patients, magnetic resonance imaging results, serological diagnoses, therapeutic measures and outcomes of treatments are described in this report.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The clinical characteristics and serological diagnoses of all BS patients were greatly improved after the administration of tofacitinib treatment. All patients reached clinical remission of polyarthritis and improvements in the erythrocyte sedimentation rate (ESR) and levels of C-reactive protein (CRP) and inflammatory cytokines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Tofacitinib, a Janus kinase (JAK) inhibitor, is a promising agent for BS patients who have unsatisfactory responses to corticosteroids, traditional disease-modifying antirheumatic drugs, and biological agents.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-021-00634-x","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T13:02:59Z","timestamp":1636981379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients"],"prefix":"10.1186","volume":"19","author":[{"given":"Song","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-0941","authenticated-orcid":false,"given":"Huasong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"issue":"1","key":"634_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng720","volume":"29","author":"C Miceli-Richard","year":"2001","unstructured":"Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hafner R, et al. CARD15 mutations in Blau syndrome. Nat Genet. 2001;29(1):19\u201320. https:\/\/doi.org\/10.1038\/ng720.","journal-title":"Nat Genet"},{"issue":"3","key":"634_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1182\/blood-2004-07-2972","volume":"105","author":"N Kanazawa","year":"2005","unstructured":"Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood. 2005;105(3):1195\u20137. https:\/\/doi.org\/10.1182\/blood-2004-07-2972.","journal-title":"Blood."},{"issue":"5","key":"634_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0022-3476(85)80394-2","volume":"107","author":"EB Blau","year":"1985","unstructured":"Blau EB. Familial granulomatous arthritis, iritis, and rash. J Pediatr. 1985;107(5):689\u201393. https:\/\/doi.org\/10.1016\/S0022-3476(85)80394-2.","journal-title":"J Pediatr"},{"issue":"6","key":"634_CR4","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/rheumatology\/keu437","volume":"54","author":"CD Rose","year":"2015","unstructured":"Rose CD, Pans S, Casteels I, Anton J, Bader-Meunier B, Brissaud P, et al. Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. Rheumatology (Oxford). 2015;54(6):1008\u201316. https:\/\/doi.org\/10.1093\/rheumatology\/keu437.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"634_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nri1086","volume":"3","author":"N Inohara","year":"2003","unstructured":"Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol. 2003;3(5):371\u201382. https:\/\/doi.org\/10.1038\/nri1086.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"634_CR6","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/01.bor.0000169362.61443.52","volume":"17","author":"CD Rose","year":"2005","unstructured":"Rose CD, Martin TM. Caspase recruitment domain 15 mutations and rheumatic diseases. Curr Opin Rheumatol. 2005;17(5):579\u201385. https:\/\/doi.org\/10.1097\/01.bor.0000169362.61443.52.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"634_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/art.25035","volume":"62","author":"K Yasui","year":"2010","unstructured":"Yasui K, Yashiro M, Tsuge M, Manki A, Takemoto K, Yamamoto M, et al. Thalidomide dramatically improves the symptoms of early-onset sarcoidosis\/Blau syndrome: its possible action and mechanism. Arthritis Rheum. 2010;62(1):250\u20137. https:\/\/doi.org\/10.1002\/art.25035.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"634_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.autrev.2012.07.028","volume":"12","author":"P Sfriso","year":"2012","unstructured":"Sfriso P, Caso F, Tognon S, Galozzi P, Gava A, Punzi L. Blau syndrome, clinical and genetic aspects. Autoimmun Rev. 2012;12(1):44\u201351. https:\/\/doi.org\/10.1016\/j.autrev.2012.07.028.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"634_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13075-019-2017-5","volume":"21","author":"J Chen","year":"2019","unstructured":"Chen J, Luo Y, Zhao M, Wu D, Yang Y, Zhang W, et al. Effective treatment of TNFalpha inhibitors in Chinese patients with Blau syndrome. Arthritis Res Ther. 2019;21(1):236. https:\/\/doi.org\/10.1186\/s13075-019-2017-5.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"634_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/acr2.11112","volume":"2","author":"W Damsky","year":"2020","unstructured":"Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of multiorgan sarcoidosis with tofacitinib. ACR Open Rheumatol. 2020;2(2):106\u20139. https:\/\/doi.org\/10.1002\/acr2.11112.","journal-title":"ACR Open Rheumatol"},{"issue":"12","key":"634_CR11","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.autrev.2014.08.010","volume":"13","author":"F Caso","year":"2014","unstructured":"Caso F, Costa L, Rigante D, Vitale A, Cimaz R, Lucherini OM, et al. Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev. 2014;13(12):1220\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.010.","journal-title":"Autoimmun Rev"},{"key":"634_CR12","doi-asserted-by":"publisher","first-page":"513782","DOI":"10.1155\/2013\/513782","volume":"2013","author":"F Caso","year":"2013","unstructured":"Caso F, Rigante D, Vitale A, Lucherini OM, Costa L, Atteno M, et al. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol. 2013;2013:513782.","journal-title":"Int J Rheumatol"},{"issue":"3","key":"634_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3109\/14397595.2013.843755","volume":"24","author":"F Caso","year":"2014","unstructured":"Caso F, Cantarini L, Lucherini OM, Sfriso P, Fioretti M, Costa L, et al. Working the endless puzzle of hereditary autoinflammatory disorders. Mod Rheumatol. 2014;24(3):381\u20139. https:\/\/doi.org\/10.3109\/14397595.2013.843755.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"634_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1744-313X.2011.00998.x","volume":"38","author":"MC Jimenez-Martinez","year":"2011","unstructured":"Jimenez-Martinez MC, Cruz F, Groman-Lupa S, Zenteno JC. Immunophenotyping in peripheral blood mononuclear cells, aqueous humour and vitreous in a Blau syndrome patient caused by a novel NOD2 mutation. Int J Immunogenet. 2011;38(3):233\u201342. https:\/\/doi.org\/10.1111\/j.1744-313X.2011.00998.x.","journal-title":"Int J Immunogenet"},{"issue":"19","key":"634_CR15","doi-asserted-by":"publisher","first-page":"12955","DOI":"10.1074\/jbc.274.19.12955","volume":"274","author":"J Bertin","year":"1999","unstructured":"Bertin J, Nir WJ, Fischer CM, Tayber OV, Errada PR, Grant JR, et al. Human CARD4 protein is a novel CED-4\/Apaf-1 cell death family member that activates NF-kappaB. J Biol Chem. 1999;274(19):12955\u20138. https:\/\/doi.org\/10.1074\/jbc.274.19.12955.","journal-title":"J Biol Chem"},{"issue":"21","key":"634_CR16","doi-asserted-by":"publisher","first-page":"14560","DOI":"10.1074\/jbc.274.21.14560","volume":"274","author":"N Inohara","year":"1999","unstructured":"Inohara N, Koseki T, Del Peso L, Hu Y, Yee C, Chen S, et al. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J Biol Chem. 1999;274(21):14560\u20137. https:\/\/doi.org\/10.1074\/jbc.274.21.14560.","journal-title":"J Biol Chem"},{"issue":"7","key":"634_CR17","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1074\/jbc.M008072200","volume":"276","author":"Y Ogura","year":"2001","unstructured":"Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1\/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem. 2001;276(7):4812\u20138. https:\/\/doi.org\/10.1074\/jbc.M008072200.","journal-title":"J Biol Chem"},{"issue":"4","key":"634_CR18","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1074\/jbc.M009728200","volume":"276","author":"N Inohara","year":"2001","unstructured":"Inohara N, Ogura Y, Chen FF, Muto A, Nunez G. Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J Biol Chem. 2001;276(4):2551\u20134. https:\/\/doi.org\/10.1074\/jbc.M009728200.","journal-title":"J Biol Chem"},{"issue":"8","key":"634_CR19","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/embo-reports\/kve155","volume":"2","author":"SE Girardin","year":"2001","unstructured":"Girardin SE, Tournebize R, Mavris M, Page AL, Li X, Stark GR, et al. CARD4\/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO Rep. 2001;2(8):736\u201342. https:\/\/doi.org\/10.1093\/embo-reports\/kve155.","journal-title":"EMBO Rep"},{"issue":"2","key":"634_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/jcp.20739","volume":"209","author":"B Begue","year":"2006","unstructured":"Begue B, Dumant C, Bambou JC, Beaulieu JF, Chamaillard M, Hugot JP, et al. Microbial induction of CARD15 expression in intestinal epithelial cells via toll-like receptor 5 triggers an antibacterial response loop. J Cell Physiol. 2006;209(2):241\u201352. https:\/\/doi.org\/10.1002\/jcp.20739.","journal-title":"J Cell Physiol"},{"issue":"12","key":"634_CR21","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.bcp.2010.07.016","volume":"80","author":"A Lecat","year":"2010","unstructured":"Lecat A, Piette J, Legrand-Poels S. The protein Nod2: an innate receptor more complex than previously assumed. Biochem Pharmacol. 2010;80(12):2021\u201331. https:\/\/doi.org\/10.1016\/j.bcp.2010.07.016.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"634_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1083\/jcb.200502153","volume":"170","author":"N Barnich","year":"2005","unstructured":"Barnich N, Aguirre JE, Reinecker HC, Xavier R, Podolsky DK. Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-{kappa} B activation in muramyl dipeptide recognition. J Cell Biol. 2005;170(1):21\u20136. https:\/\/doi.org\/10.1083\/jcb.200502153.","journal-title":"J Cell Biol"},{"issue":"1","key":"634_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev.pathol.4.110807.092239","volume":"4","author":"G Chen","year":"2009","unstructured":"Chen G, Shaw MH, Kim YG, Nunez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol. 2009;4(1):365\u201398. https:\/\/doi.org\/10.1146\/annurev.pathol.4.110807.092239.","journal-title":"Annu Rev Pathol"},{"issue":"9","key":"634_CR24","doi-asserted-by":"publisher","first-page":"e44818","DOI":"10.1371\/journal.pone.0044818","volume":"7","author":"T Zhou","year":"2012","unstructured":"Zhou T, Zhang W, Sweiss NJ, Chen ES, Moller DR, Knox KS, et al. Peripheral blood gene expression as a novel genomic biomarker in complicated sarcoidosis. PLoS One. 2012;7(9):e44818. https:\/\/doi.org\/10.1371\/journal.pone.0044818.","journal-title":"PLoS One"},{"issue":"26","key":"634_CR25","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","volume":"379","author":"W Damsky","year":"2018","unstructured":"Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540\u20136. https:\/\/doi.org\/10.1056\/NEJMoa1805958.","journal-title":"N Engl J Med"},{"issue":"3","key":"634_CR26","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","volume":"82","author":"W Damsky","year":"2020","unstructured":"Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82(3):612\u201321. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.098.","journal-title":"J Am Acad Dermatol"},{"key":"634_CR27","first-page":"186","volume":"16","author":"S Onuora","year":"2020","unstructured":"Onuora S. Tofacitinib alleviates pain in RA, PsA and AS. Nat Rev Rheumatol. 2020;16:186.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"634_CR28","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234\u201343. https:\/\/doi.org\/10.4049\/jimmunol.1003668.","journal-title":"J Immunol"},{"issue":"11","key":"634_CR29","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1002\/art.22966","volume":"56","author":"JI Arostegui","year":"2007","unstructured":"Arostegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P, et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 2007;56(11):3805\u201313. https:\/\/doi.org\/10.1002\/art.22966.","journal-title":"Arthritis Rheum"},{"key":"634_CR30","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/rheumatology\/kes019","volume":"51","author":"K Minden","year":"2012","unstructured":"Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology. 2012;51:1407\u201315.","journal-title":"Rheumatology"},{"issue":"9","key":"634_CR31","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.38741","volume":"66","author":"H Schmeling","year":"2014","unstructured":"Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German biologics JIA registry. Arthritis Rheum. 2014;66(9):2580\u20139. https:\/\/doi.org\/10.1002\/art.38741.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"634_CR32","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40884","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheum. 2019;71(6):846\u201363. https:\/\/doi.org\/10.1002\/art.40884.","journal-title":"Arthritis Rheum"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00634-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00634-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00634-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T13:11:32Z","timestamp":1636981892000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00634-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["634"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00634-x","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]},"assertion":[{"value":"13 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical Committees of the Guangzhou Women and Children\u2019s Medical Center, Guangzhou, China. Written informed consent for participation in this study was obtained from the parents of the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the parents of all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}